Kiora publishes results from Phase 1 study demonstrating safety, tolerability and efficacy of KIO-101
Ophthalmology Times Europe,
KIO-101 is the designation for topical delivery and KIO-104 is the designation for intravitreal injection.
Kiora publishes results from study demonstrating safety, tolerability and efficacy of KIO-101 for treatment of inflammation of the eye
Ophthalmology Times,
(Image Credit: AdobeStock/Davizro Photography) Kiora Pharmaceuticals Inc announced the publication of results from a Phase 1…
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Clinical Research News,
August 23, 2023 -- Encinitas, CA -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it…
Kiora Pharmaceuticals granted European and US patents for local ocular delivery of the KIO-100 family of compounds
Ophthalmology Times Europe,
In posterior non-infectious uveitis, the company's KIO-104 product demonstrated promising results in a Phase 1b clinical study…